Prosight Management, LP Cellectis S.A. Transaction History

Prosight Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $697,695 - $1.12 Million	-87,103 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$11.94 - $16.09 $12,739 - $17,168	1,067 Added 1.24%	87,103 $1.1 Million
Q2 2021 Aug 13, 2021	SELL	$14.36 - $20.93 $744,767 - $1.09 Million	-51,864 Reduced 37.61%	86,036 $1.33 Million
Q1 2021 May 14, 2021	BUY	$18.19 - $33.25 $2.51 Million - $4.59 Million	137,900 New	137,900 $2.79 Million
Q4 2020 Feb 12, 2021	SELL	$15.87 - $31.64 $2.94 Million - $5.86 Million	-185,180 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$15.7 - $20.84 $1.43 Million - $1.9 Million	-91,397 Reduced 33.05%	185,180 $3.43 Million
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $2.27 Million - $5.81 Million	276,577 New	276,577 $4.92 Million
Q3 2018 Nov 15, 2018	SELL	$25.99 - $30.6 $503,894 - $593,272	-19,388 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $538,598 - $747,019	19,388 New	19,388 $548,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.